DSpace Repository

SPUTNIK-V REACTOGENICITY AND IMMUNOGENICITY IN THE BLOOD AND MUCOSA: A PROSPECTIVE COHORT STUDY

Show simple item record

dc.contributor.author Yegorov, Sergey
dc.contributor.author Kadyrova, Irina
dc.contributor.author Negmetzhanov, Baurzhan
dc.contributor.author Kolesnikova, Yevgeniya
dc.contributor.author Kolesnichenko, Svetlana
dc.contributor.author Korshukov, Ilya
dc.contributor.author Baiken, Yeldar
dc.contributor.author Matkarimov, Bakhyt
dc.contributor.author Miller, Matthew S.
dc.date.accessioned 2023-02-17T10:21:11Z
dc.date.available 2023-02-17T10:21:11Z
dc.date.issued 2022
dc.identifier.citation Yegorov, S., Kadyrova, I., Negmetzhanov, B., Kolesnikova, Y., Kolesnichenko, S., Korshukov, I., Baiken, Y., Matkarimov, B., Miller, M. S., Hortelano, G. H., & Babenko, D. (2022). Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-17514-3 en_US
dc.identifier.uri http://nur.nu.edu.kz/handle/123456789/6963
dc.description.abstract Sputnik-V (Gam-COVID-Vac) is a heterologous, recombinant adenoviral (rAdv) vector-based, COVID- 19 vaccine now used in > 70 countries. Yet there is a shortage of data on this vaccine’s performance in diverse populations. Here, we performed a prospective cohort study to assess the reactogenicity and immunologic outcomes of Sputnik-V vaccination in Kazakhstan. COVID-19-free participants (n = 82 at baseline) were followed at day 21 after Sputnik-V dose 1 (rAd5) and dose 2 (rAd26). Self-reported local and systemic adverse events were captured using questionnaires. Blood and nasopharyngeal swabs were collected to perform SARS-CoV-2 diagnostic and immunologic assays. We observed that most of the reported adverse events were mild-to-moderate injection site or systemic reactions, no severe or potentially life-threatening conditions were reported, and dose 1 appeared to be more reactogenic than dose 2. The seroconversion rate was 97% post-dose 1, remaining the same post-dose 2. The proportion of participants with detectable virus neutralization was 83% post-dose 1, increasing to 98% post-dose 2, with the largest relative increase observed in participants without prior COVID- 19 exposure. Dose 1 boosted nasal S-IgG and S-IgA, while the boosting effect of dose 2 on mucosal S-IgG, but not S-IgA, was only observed in subjects without prior COVID-19. Systemically, vaccination reduced serum levels of growth regulated oncogene (GRO), which correlated with an elevation in blood platelet count. Overall, Sputnik-V dose 1 elicited both blood and mucosal SARS-CoV-2 immunity, while the immune boosting effect of dose 2 was minimal. Thus, adjustments to the current vaccine dosing regimen are necessary to optimize immunization efficacy and cost-effectiveness. While Sputnik-V reactogenicity is similar to that of other COVID-19 vaccines, the induced alterations to the GRO/platelet axis warrant investigation of the vaccine’s effects on systemic immunology. en_US
dc.language.iso en en_US
dc.publisher Scientific Reports en_US
dc.rights Attribution-NonCommercial-ShareAlike 3.0 United States *
dc.rights.uri http://creativecommons.org/licenses/by-nc-sa/3.0/us/ *
dc.subject Type of access: Open Access en_US
dc.subject Sputnik‑V en_US
dc.subject COVID- 19 vaccine en_US
dc.title SPUTNIK-V REACTOGENICITY AND IMMUNOGENICITY IN THE BLOOD AND MUCOSA: A PROSPECTIVE COHORT STUDY en_US
dc.type Article en_US
workflow.import.source science


Files in this item

The following license files are associated with this item:

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 3.0 United States Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 3.0 United States